XML 32 R18.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Segment Information | 12 Months Ended
--- | ---
Jun. 30, 2022
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | Note 12. Segment Information: The Company operates under two operating segments, Protein Sciences and Diagnostics and Genomics. The Company’s Protein Sciences segment is comprised of the reagent solutions and analytical solutions. These businesses manufacture consumables used for conducting laboratory experiments by both industry and academic scientists within the biotechnology and biomedical life science fields. No customer in the Protein Sciences segment accounted for more than 10% of the segment’s net sales for the years ended June 30, 2022, 2021, and 2020. The Company’s Diagnostics and Genomics segment is comprised of diagnostics reagents, genomics, and molecular diagnostics, which includes our Exosome and Asuragen acquisitions. Diagnostics reagents develops and manufactures a range of controls and calibrators used with diagnostic equipment and as proficiency testing tools, as well as other reagents incorporated into diagnostic kits. Genomics and molecular diagnostics consists of exosome-based diagnostics products for various pathologies, as well as tissue-based in-situ hybridization assays for research in clinical use. No customer in the Diagnostics and Genomics segment accounted for more than 10% of the segment’s net sales for the fiscal years ended June 30, 2022, 2021, and 2020. There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term. Following is financial information relating to the operating segments (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | Year Ended June 30,
​ | 2022 |  | 2021 |  | 2020
Net sales: | ​ |  | ​ | ​ | ​ | ​ | ​ | ​
Protein Sciences | $ | 832,311 |  | $ | 704,564 | ​ | $ | 555,352
Diagnostics and Genomics |  | 274,843 | ​ |  | 227,744 | ​ |  | 184,549
Intersegment |  | (1,555) | ​ |  | (1,276) | ​ |  | (1,210)
Consolidated net sales | $ | 1,105,599 |  | $ | 931,032 | ​ | $ | 738,691
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income: |  |  | ​ |  |  | ​ |  |
Protein Sciences(1) | $ | 377,623 |  | $ | 330,225 | ​ | $ | 234,929
Diagnostics and Genomics |  | 48,977 | ​ |  | 38,425 | ​ |  | 14,965
Segment operating income |  | 426,600 | ​ |  | 368,650 | ​ |  | 249,894
Costs recognized on sale of acquired inventory |  | (1,596) | ​ |  | (1,565) | ​ |  | —
Amortization of acquisition related intangible assets |  | (73,054) | ​ |  | (64,239) | ​ |  | (60,865)
Impact of partially owned consolidated subsidiaries(1) |  | (2,393) | ​ |  | (1,505) | ​ |  | —
Gain on escrow settlement | ​ | — | ​ | ​ | — | ​ | ​ | 7,169
Acquisition related expenses |  | 19,070 | ​ |  | (7,114) | ​ |  | (416)
Eminence impairment | ​ | (18,715) | ​ | ​ | — | ​ | ​ | —
Stock based compensation, inclusive of employer taxes |  | (46,401) | ​ |  | (51,846) | ​ |  | (34,262)
Restructuring costs |  | (1,640) | ​ |  | (142) | ​ |  | (87)
Corporate general, selling, and administrative expenses(1) |  | (5,281) | ​ |  | (4,943) | ​ |  | (4,015)
Consolidated operating income | $ | 296,590 |  | $ | 237,296 | ​ | $ | 157,419
​ (1)Adjusted operating income for fiscal 2021 have been updated for comparability to fiscal 2022 for the inclusion of the impact of partially-owned consolidated subsidiaries on the Company’s adjusted operating income. ​ The Company has some integrated facilities that serve both segments. As such, asset and capital expenditure information by operating segment has not been provided and is not available, since the Company does not produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each operating segment’s operating results, it is not discretely identifiable. ​ The Company has disclosed sales by geographic area based on the location of the customer or distributor in Note 2. The Company has disclosed dis-aggregated product and service revenue by consumables, instruments, and services in Note 2. The Company considers total instrument and total service revenue to represent similar groups of products in the fiscal years presented. The Company considered our consumables sold in the Protein Sciences and Diagnostics and Genomics segments to represent different groups of products and therefore have separately disclosed the related consumables revenue (in thousands) : ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended June 30,
​ |  | 2022 |  | 2021 |  | 2020
Consumables revenue - Protein Sciences | ​ | $ | 646,952 | ​ | $ | 557,037 | ​ | $ | 431,052
Consumables revenue - Diagnostics and Genomics | ​ |  | 243,922 | ​ |  | 194,948 | ​ |  | 171,590
Total consumable revenue | ​ | $ | 890,874 | ​ | $ | 751,985 | ​ | $ | 602,642
​ ​ The following is financial information relating to geographic areas (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year ended June 30,
​ |  | 2022 |  | 2021
Long-lived assets: | ​ | ​ | ​ | ​ | ​ | ​
United States and Canada | ​ | $ | 203,732 |  | $ | 190,501
Europe |  |  | 16,223 | ​ |  | 13,949
Asia | ​ |  | 3,287 | ​ |  | 3,457
Total long-lived assets | ​ | $ | 223,242 |  | $ | 207,907
Intangible assets: | ​ |  |  | ​ |  |
United States and Canada | ​ | $ | 523,536 |  | $ | 594,512
Europe | ​ |  | 6,281 | ​ |  | 9,369
Asia | ​ |  | 1,705 | ​ |  | 12,087
Total intangible assets | ​ | $ | 531,522 |  | $ | 615,968
​ Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration